Blog

  • Home grown ideas place physio in patients’ hands

    Home grown ideas place physio in patients’ hands

    New research is testing a new way to meet the rapidly growing demand for physiotherapy in our public hospitals.

    A clinical trial at four hospitals, including Hornsby and Royal North Shore, is studying whether some patients can successfully undertake physiotherapy exercises at home and still experience the same benefit provided by attending a hospital clinic.

    “Demand for physio is increasing rapidly because we have an aging population and because clinicians and consumers have a growing appreciation of its benefits for some conditions,” said Professor Lisa Harvey from Northern Sydney Local Health District and the Kolling Institute.

    “But its popularity has created a patient access and equity issue. There are simply not enough physiotherapists to meet the demand in the NSW health system and in some districts the waiting list for face-to-face treatment is very long.”

    In a project funded through Sydney Health Partners, Professor Harvey, in collaboration with NSW Health physiotherapists and academics, is using a web-based application to provide trial participants with individually-customised sets of exercises to do at home.

    “After a face-to-face assessment, a physiotherapist uses our web application to select and compile a set of exercises suitable for their condition,” said Professor Harvey. “The patient is then given a unique website link to their individual exercise program.”

    “They also get messages of encouragement via text messages, and a physiotherapist telephones the patient after two weeks to give them advice, support and reassurance.”

    The project is testing the theory that some patients experience better physio outcomes when not dependent on face-to-face treatment.

    “In many cases we believe it’s better for patients if they come to see their problem as something they can address if given appropriate support,” said Professor Harvey.

  • Recognition for research excellence

    Recognition for research excellence

    Congratulations to Professor David Hunter who’s received a prestigious University of Sydney Vice Chancellor’s award for outstanding research.

    The Kolling researcher and rheumatology clinician is regarded as the world’s leading expert in osteoarthritis.

    Professor Hunter’s research has had a significant and lasting impact in the field of osteoarthritis, influencing clinical practice and access to evidence-based care. His work has helped to ensure low-value, fragmented care has been replaced with a co-ordinated, patient-centred system.

    The Vice-Chancellor’s Awards for Excellence celebrate exceptional performance, recognising a researcher’s impact, leadership and engagement with industry and the community.

    Professor Hunter welcomed the award, and acknowledged his team.

    “It takes a village to make a difference to a disease such as osteoarthritis, and I am privileged to work with an amazing team who are the real winners of this award,” he said.

  • Northern Sydney leading the way with arthritis research and clinical care

    Northern Sydney leading the way with arthritis research and clinical care

    The latest exciting research into musculoskeletal disease has been unveiled during the inaugural Northern Lights showcase.

    Close to 200 people attended the jam packed event in the Kolling auditorium, including clinicians, researchers and many people living with arthritic pain.

    RNSH Head of Rheumatology Professor Lyn March addressed the event, detailing the devastating cost of the disease to individuals and the broader community, with many sufferers forced out of the workforce prematurely.

    “Musculoskeletal disease is the leading cause of disability in Australia, affecting around seven million people and costing about $6 billion to the health budget,” Lyn said.

    “It affects men, women and children of all ages in many different ways. Every patient will have a different journey, and in many cases, a different response to individual treatments.”

    Rheumatology clinician researcher Professor David Hunter described how healthcare is evolving from the world leading research being undertaken within the Kolling Institute and at Royal North Shore Hospital.

    “We have a living lab here, developing research and incorporating it directly into clinical care, and improving the lives of those living with these diseases.

    “We have strong interactions with scientists and researchers as well as a great knowledge about the best care for musculoskeletal conditions,” David said.

    Researchers discussed the value of medication and surgery, while focusing on the long term benefits of a multi-disciplinary approach with evidence-based strategies, such as the Osteoarthritis Chronic Care Program.

    Researchers also confirmed new exciting stem cell technology will be trialled over the next few years, where stem cells will be injected into problem areas to alleviate pain.

    In the short term however, there’ll be a greater focus on community education, including the use of regular text messages to help patients manage their conditions.

    The national Arthritis Biospecimens Bank – A3BC – is also being set up to identify the right treatments for patients, as well as the causes for arthritis and possible cures.

    The inaugural Northern Lights showcase was part of a series highlighting the remarkable advances in research and innovation across the Northern Sydney Local Health District.

    The next event will be held in the coming months.

  • New world leading technology to guide future bowel cancer treatment

    New world leading technology to guide future bowel cancer treatment

    Research capabilities within the Kolling Institute have been significantly broadened with new technology to assist the examination of bowel cancer.

    Representatives from Sydney University, the Kolling and Bowel Cancer Australia attended the official opening of the mass spectrometry core lab – the first of its type on a hospital campus and one of the best analytical facilities in the world.

    Professor Mark Molloy, Lawrence Penn chair of Bowel Cancer Research said the sophisticated technology will measure molecules with very high accuracy, providing researchers with valuable and practical information about how bowel cancer develops.

    “Years ago we could measure 400-500 proteins within a sample, compared with more than 6,000 proteins now,” Mark said.

    “This means our data is more accurate and we have a clearer understanding of the molecular make-up of tumours.

    “We would like to see our research influence future bowel cancer treatment by indicating which patients are at disease risk, which cancers will benefit from chemotherapy and radiotherapy, and which cancers are likely to recur,” Mark said.

    Mark’s research has been further boosted with a cheque for $500,000 from Bowel Cancer Research Foundation Australia. Chairman Richard Griffin said he was very confident it would lead to some remarkable and ground breaking research, and bring relief to so many people.

  • New medication may offer long-acting relief for those with knee osteoarthritis

    New medication may offer long-acting relief for those with knee osteoarthritis

    A study has been launched to investigate the benefits of a new injectable medication for those with knee osteoarthritis.

    The condition can have a profound impact on a person’s life, leading to physical limitations, ongoing pain and joint instability.

    There are broader implications too which can make it difficult for those with the condition to engage in social, community and occupational activities.

    Significant resources and expertise are being directed towards the disease, and a number of clinical trials and research studies are underway to develop new interventions and tests that may alleviate the symptoms of the condition.

    One of these promising trials is being led by Professor David Hunter and his team from the Kolling Institute and Royal North Shore Hospital.

    The Excellence Study will evaluate a new injectable medication that has been formulated to provide both short-term and long-acting relief from pain, inflammation and mobility impairments.

    Many current medications for knee osteoarthritis offer only short-term relief, while this new medication may offer relief for up to six months. 

    Volunteers are being recruited for the study and further community support is needed.

    Details about the eligibility criteria can be found in the registration survey form.

    Interested volunteers can click on the link provided in the form to register their interest for the study.

    To find out more: https://redcap.sydney.edu.au/surveys/?s=4T7XWDW33T

    Contact: Tatyana Fedorova 9463 1774

NSWGOV logo